Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Jun 16;27(12):3862.
doi: 10.3390/molecules27123862.

Analysis of Pros and Cons in Using [68Ga]Ga-PSMA-11 and [18F]PSMA-1007: Production, Costs, and PET/CT Applications in Patients with Prostate Cancer

Costantina Maisto  1 , Michela Aurilio  2 , Anna Morisco  1 , Roberta de Marino  1 , Monica Josefa Buonanno Recchimuzzo  1 , Luciano Carideo  1 , Laura D'Ambrosio  1 , Francesca Di Gennaro  1 , Aureliana Esposito  1 , Paolo Gaballo  1 , Valentina Pirozzi Palmese  1 , Valentina Porfidia  1 , Marco Raddi  1 , Alfredo Rossi  1 , Elisabetta Squame  1 , Secondo Lastoria  1
Affiliations

Analysis of Pros and Cons in Using [68Ga]Ga-PSMA-11 and [18F]PSMA-1007: Production, Costs, and PET/CT Applications in Patients with Prostate Cancer

Costantina Maisto et al. Molecules. .

Abstract

The aim of this work is to compare [68Ga]Ga-PSMA-11 and [18F]PSMA-1007 PET/CT as imaging agents in patients with prostate cancer (PCa). Comparisons were made by evaluating times and costs of the radiolabeling process, imaging features including pharmacokinetics, and impact on patient management. The analysis of advantages and drawbacks of both radioligands might help to make a better choice based on firm data. For [68Ga]Ga-PSMA-11, the radiochemical yield (RCY) using a low starting activity (L, average activity of 596.55 ± 37.97 MBq) was of 80.98 ± 0.05%, while using a high one (H, average activity of 1436.27 ± 68.68 MBq), the RCY was 71.48 ± 0.04%. Thus, increased starting activities of [68Ga]-chloride negatively influenced the RCY. A similar scenario occurred for [18F]PSMA-1007. The rate of detection of PCa lesions by Positron Emission Tomography/Computed Tomography (PET/CT) was similar for both radioligands, while their distribution in normal organs significantly differed. Furthermore, similar patterns of biodistribution were found among [18F]PSMA-1007, [68Ga]Ga-PSMA-11, and [177Lu]Lu-PSMA-617, the most used agent for RLT. Moreover, the analysis of economical aspects for each single batch of production corrected for the number of allowed PET/CT examinations suggested major advantages of [18F]PSMA-1007 compared with [68Ga]Ga-PSMA-11. Data from this study should support the proper choice in the selection of the PSMA PET radioligand to use on the basis of the cases to study.

Keywords: PCa; PSMA; RCP; [18F]PSMA-1007; [68Ga]Ga-PSMA-11; [68Ge]/[68Ga] generator; cyclotron RCY.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Positive PET/CT scans performed with (A) [18F]PSMA-1007 (70–90 min p.i.) and with (B) [68Ga]Ga-PSMA-11 (45–60 min p.i.) for the same patient. Planar images (C) acquired with SPECT/CT γ-camera 96 h after administration of [177Lu]Lu-PSMA-617.
Figure 2
Figure 2
Negative PET/CT scans: patient (A) was examined with [18F]PSMA-1007, and patient (B) was examined with [68Ga]Ga-PSMA-11.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Eeles R., Ni Raghallaigh H. Men with a susceptibility to prostate cancer and the role of genetic based screening. Transl. Androl. Urol. 2018;7:61–69. doi: 10.21037/tau.2017.12.30. - DOI - PMC - PubMed
    1. Lengana T., Lawal I.O., Rensburg C.V., Mokoala K.M.G., Moshokoa E., Ridgard T., Vorster M., Sathekge M.M. A comparison of the diagnostic performance of 18F-PSMA-1007 and 68GA-PSMA-11 in the same patients presenting with early biochemical recurrence. Hell. J. Nucl. Med. 2021;24:178–185. doi: 10.1967/s002449912401. - DOI - PubMed
    1. Umbricht C.A., Benešová M., Schmid R.M., Türler A., Schibli R., van der Meulen N.P., Müller C. 44Sc-PSMA-617 for radiotheragnostics in tandem with 177Lu-PSMA-617-preclinical investigations in comparison with 68Ga-PSMA-11 and 68Ga-PSMA-617. EJNMMI Res. 2017;7:9. doi: 10.1186/s13550-017-0257-4. - DOI - PMC - PubMed
    1. Parker C., Castro E., Fizazi K., Heidenreich A., Ost P., Procopio G., Tombal B., Gillessen S. Prostate cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 2020;31:1119–1134. doi: 10.1016/j.annonc.2020.06.011. - DOI - PubMed
    1. Fendler W.P., Rahbar K., Herrmann K., Kratochwil C., Eiber M. 177Lu-PSMA Radioligand Therapy for Prostate Cancer. J. Nucl. Med. 2017;58:1196–1200. doi: 10.2967/jnumed.117.191023. - DOI - PubMed